Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.42) per share. This is a 93.01 percent increase over losses of $(6.01) per share from the same period last year.
Is The Evergrande Crisis Over?
The looming collapse of China Evergrande Group (OTC:EVGPF), the world’s most indebted property developer, has roiled financial markets for months, threatening a contagion with far-reaching implications on China and the wider economy.
